MX2020009773A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2020009773A
MX2020009773A MX2020009773A MX2020009773A MX2020009773A MX 2020009773 A MX2020009773 A MX 2020009773A MX 2020009773 A MX2020009773 A MX 2020009773A MX 2020009773 A MX2020009773 A MX 2020009773A MX 2020009773 A MX2020009773 A MX 2020009773A
Authority
MX
Mexico
Prior art keywords
combination therapy
inhibitor
effective amount
methods
kinase
Prior art date
Application number
MX2020009773A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MX2020009773A publication Critical patent/MX2020009773A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Abstract

En el presente documento se proporcionan métodos para tratar enfermedades, como el cáncer, usando una terapia de combinación. En determinadas realizaciones, los métodos comprenden administrar una cantidad eficaz de un inhibidor de fosfoinositido-3-quinasa (PI3K) y una cantidad eficaz de un inhibidor de tirosina quinasa de Bruton (BTK) a un paciente.
MX2020009773A 2018-03-21 2019-03-20 Terapia de combinacion. MX2020009773A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646314P 2018-03-21 2018-03-21
PCT/US2019/023172 WO2019183226A1 (en) 2018-03-21 2019-03-20 Combination therapy

Publications (1)

Publication Number Publication Date
MX2020009773A true MX2020009773A (es) 2020-10-08

Family

ID=67988025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009773A MX2020009773A (es) 2018-03-21 2019-03-20 Terapia de combinacion.

Country Status (16)

Country Link
US (1) US20210000838A1 (es)
EP (1) EP3768258A4 (es)
JP (1) JP2021517116A (es)
KR (1) KR20200135439A (es)
CN (1) CN112165939A (es)
AU (1) AU2019238207A1 (es)
BR (1) BR112020019082A2 (es)
CA (1) CA3093847A1 (es)
EA (1) EA202092154A1 (es)
IL (1) IL277336A (es)
MA (1) MA52090A (es)
MX (1) MX2020009773A (es)
SG (1) SG11202009137PA (es)
TW (1) TW202002983A (es)
WO (1) WO2019183226A1 (es)
ZA (1) ZA202005661B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024907A2 (pt) 2011-03-28 2016-12-20 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
TWI739887B (zh) 2016-08-19 2021-09-21 英屬開曼群島商百濟神州有限公司 使用包含btk抑制劑的組合產品治療癌症
KR20200009088A (ko) 2017-05-23 2020-01-29 메이 파마, 아이엔씨. 병용 요법
KR20200020902A (ko) 2017-06-26 2020-02-26 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
JP2020531414A (ja) 2017-08-14 2020-11-05 エムイーアイ ファーマ，インク． 併用療法
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
US20220241285A1 (en) * 2019-06-10 2022-08-04 Beigene Switzerland Gmbh Oral capsule and preparation method therefor
TW202112376A (zh) * 2019-06-10 2021-04-01 英屬開曼群島商百濟神州有限公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
CN110922409A (zh) * 2019-12-19 2020-03-27 武汉九州钰民医药科技有限公司 制备btk抑制剂泽布替尼的方法
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013024907A2 (pt) * 2011-03-28 2016-12-20 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
MX369503B (es) * 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
US10328080B2 (en) * 2013-12-05 2019-06-25 Acerta Pharma, B.V. Therapeutic combination of PI3K inhibitor and a BTK inhibitor
TW201613644A (en) * 2014-06-17 2016-04-16 Acerta Pharma Bv Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
TW201618774A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法

Also Published As

Publication number Publication date
EA202092154A1 (ru) 2021-03-22
CA3093847A1 (en) 2019-09-26
TW202002983A (zh) 2020-01-16
EP3768258A4 (en) 2022-01-12
EP3768258A1 (en) 2021-01-27
US20210000838A1 (en) 2021-01-07
CN112165939A (zh) 2021-01-01
MA52090A (fr) 2021-04-21
AU2019238207A1 (en) 2020-10-01
KR20200135439A (ko) 2020-12-02
WO2019183226A1 (en) 2019-09-26
SG11202009137PA (en) 2020-10-29
JP2021517116A (ja) 2021-07-15
IL277336A (en) 2020-10-29
BR112020019082A2 (pt) 2020-12-29
ZA202005661B (en) 2023-05-31

Similar Documents

Publication Publication Date Title
MX2020009773A (es) Terapia de combinacion.
MX2019003134A (es) Terapia de combinacion.
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
MX2020001727A (es) Terapia de combinacion.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
SG10201902664RA (en) Combination therapy for treating cancer
MX2019013862A (es) Terapia de combinacion.
AU2013299841A8 (en) Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a PI3K-alpha inhibitor
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2021009051A (es) Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular.
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MX2021007554A (es) Terapia de combinacion para el tratamiento de cancer.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021011529A (es) Chiauranib para el tratamiento de cáncer de pulmón microcítico.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2021001764A (es) Terapia de combinacion.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.